Tigecycline for the Treatment of Severe and Severe Complicated Clostridium difficile Infection

被引：41

作者：

Britt N.S. ^{[1
,2
,3
]}

Steed M.E. ^{[1
]}

Potter E.M. ^{[3
]}

Clough L.A. ^{[4
]}

机构：

[1] Department of Pharmacy Practice, University of Kansas School of Pharmacy, 3901 Rainbow Boulevard, MS 4047, Kansas City, KS

[2] Department of Preventive Medicine and Public Health, University of Kansas School of Medicine, Kansas City, KS

[3] Pharmacy Service, Dwight D. Eisenhower Veterans Affairs Medical Center, Leavenworth, KS

[4] Division of Infectious Diseases, Department of Medicine, University of Kansas School of Medicine, Kansas City, KS

来源：

Infectious Diseases and Therapy | 2014年 / 3卷 / 2期

基金：

美国国家卫生研究院;

关键词：

Clostridium difficile; Combination drug therapy; Tigecycline;

D O I：

10.1007/s40121-014-0050-x

中图分类号：

学科分类号：

摘要：

Introduction: Clostridium difficile infection (CDI) is a common cause of nosocomial diarrhea. Metronidazole and vancomycin are the primary treatment options for CDI, but increasing rates of antimicrobial resistance and severe, refractory disease have prompted the need for alternative agents. Tigecycline has previously demonstrated favorable in vitro activity against C. difficile isolates, but clinical data on its use in the treatment of CDI are severely lacking. The objective of this study was to describe our experience using tigecycline in the treatment of severe and severe complicated CDI.; Methods: This was a retrospective case series of hospitalized patients with severe and severe complicated CDI who were treated with tigecycline. Disease severity assessments were determined according to current practice guidelines. Diagnosis of toxigenic CDI was confirmed by polymerase chain reaction and patients were excluded if they received tigecycline for <48 h. Data were collected by review of the electronic medical record. The primary outcome was clinical cure. Secondary outcomes were sustained response, hospital mortality, and 28-day all-cause mortality.; Results: A total of 7 cases of severe and complicated CDI were reviewed. Intravenous tigecycline administered as a 100-mg loading dose followed by 50 mg twice daily resulted in clinical cure in 85.7% (n = 6/7) of cases. The majority of patients (n = 4/5) were treated with the novel triple therapy combination of tigecycline, vancomycin, and metronidazole and resulted in clinical cure in 80% (n = 4/5) cases. Sustained response at 28 days was 100% among evaluable cases (n = 5/5). Hospital mortality did not occur in any patients, and 28-day all-cause mortality was 28.6% (n = 2/7).; Conclusion: Tigecycline appears to be a reasonable addition to the therapeutic regimen in the treatment of severe or complicated CDI, including cases that are refractory to standard therapy. A prospective clinical trial confirming these observational findings is warranted. © 2014, The Author(s).

引用

页码：321 / 331

页数：10

共 27 条

[1]

Cohen S.H., Gerding D.N., Johnson S., Et al., Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA), Infect Control Hosp Epidemiol, 31, 5, pp. 431-455, (2010)

[2]

Moudgal V., Sobel J.D., Clostridium difficile colitis: a review, Hosp Pract (1995), 40, 1, pp. 139-148, (2012)

[3]

Adams S.D., Mercer D.W., Fulminant Clostridium difficile colitis, Curr Opin Crit Care, 13, 4, pp. 450-455, (2007)

[4]

Bartlett J.G., Narrative review: the new epidemic of Clostridium difficile-associated enteric disease, Ann Intern Med, 145, 10, pp. 758-764, (2006)

[5]

Loo V.G., Poirier L., Miller M.A., Et al., A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality, N Engl J Med, 353, 23, pp. 2442-2449, (2005)

[6]

Philadelphia, (2011)

[7]

Hawser S.P., Activity of tigecycline against recent European clinical isolates of Clostridium difficile, Int J Antimicrob Agents, 35, 1, pp. 97-98, (2010)

[8]

Nord C.E., Sillerstrom E., Wahlund E., Effect of tigecycline on normal oropharyngeal and intestinal microflora, Antimicrob Agents Chemother, 50, 10, pp. 3375-3380, (2006)

[9]

Nagy E., Dowzicky M.J., In vitro activity of tigecycline and comparators against a European compilation of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST), Scand J Infect Dis, 42, 1, pp. 33-38, (2010)

[10]

Hoffmann M., DeMaio W., Jordan R.A., Et al., Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects, Drug Metab Dispos, 35, 9, pp. 1543-1553, (2007)

← 1 2 3 →